Post-partum depression is a major healthcare concern and is associated with substantial morbidity. Therefore, novel pharmacological treatment options are urgently needed for the management of this condition. In this regard, a recent study published in The Lancet reported that Administration of brexanolone injection for managing post-partum depression showed significant clinical reductions in Hamilton Rating Scale for Depression (HAM-D) total score at 60 hours compared with placebo.
Furthermore, the study suggested that brexanolone injection is a novel therapeutic drug for post-partum depression having the potential to improve treatment outcomes in women with this disorder. Source: Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J. Brexanolone injection in post-partum depression: two multicentre,…
